NBY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-28), NovaBay Pharmaceuticals's share price is $0.1394. NovaBay Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.04. Hence, NovaBay Pharmaceuticals's PB Ratio of today is .
The historical rank and industry rank for NovaBay Pharmaceuticals's PB Ratio or its related term are showing as below:
During the past 13 years, NovaBay Pharmaceuticals's highest PB Ratio was 108.47. The lowest was 0.20. And the median was 5.15.
During the past 12 months, NovaBay Pharmaceuticals's average Book Value Per Share Growth Rate was -101.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -77.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -42.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NovaBay Pharmaceuticals was 58.70% per year. The lowest was -77.30% per year. And the median was -12.80% per year.
The historical data trend for NovaBay Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 18.38 | 2.36 | 1.90 | 0.52 | 1.69 |
NovaBay Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PB Ratio | Get a 7-Day Free Trial | 0.58 | 0.49 | 0.58 | 1.69 | - |
For the Biotechnology subindustry, NovaBay Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NovaBay Pharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Mar. 2024) |
= | 0.1394 | / | -0.041 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NovaBay Pharmaceuticals (AMEX:NBY) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Tommy Law | officer: Interim CFO | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Jeffrey Kunin | officer: President, DERMAdoctor, LLC | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Audrey Kunin | officer: Chief Product Officer | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Justin Hall | officer: General Counsel | 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608 |
Yongxiang Zheng | director | NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316 |
Julie Garlikov | director | 2420 17TH STREET, SUITE 220, DENVER CO 80202 |
Andrew D. Jones | officer: CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Mijia Wu | director | SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA |
Jian Ping Fu | 10 percent owner | LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125 |
Wang Xu | officer: NEO - Sr Mgr and Controller | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Swan Sit | director | 95 JACKSON STREET, NEWTON MA 02459 |
Yenyou Zheng | director | 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9 |
Xiaopei Wang | director | 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109 |
Jason Philip Raleigh | officer: Interim CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Pioneer Pharma (hong Kong) Co Ltd | 10 percent owner | FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000 |
From GuruFocus
By PRNewswire PRNewswire • 05-15-2019
By Marketwired Marketwired • 08-09-2019
By PRNewswire PRNewswire • 07-13-2020
By PRNewswire • 09-13-2023
By Marketwired Marketwired • 08-09-2019
By PRNewswire PRNewswire • 05-14-2020
By PRNewswire PRNewswire • 10-02-2020
By PRNewswire PRNewswire • 04-20-2020
By gurufocus • 08-28-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.